Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation

References

• Kyle R A, Rajkumar S V. Multiple myeloma. New England Journal of Medicine 2004; 351: 1860–1873
   PubMed Web of Science ®Google Scholar
• Cavo M, Terragna C, Martinelli G, Ronconi S, Zamagni E, Tosi P, et al. Molecular monitoring of minimal residual disease in patients in long term complete remission after allogeneic stem cell transplantation for múltiple myeloma. Blood 2000; 96: 355–357
   PubMed Web of Science ®Google Scholar
• Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli R, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. Journal of Clinical Oncology 2000; 18: 2273–2281
   PubMed Web of Science ®Google Scholar
• Bensinger W I, Buckner C D, Anasetti C, Clift R, Storb R, Barnett T, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787–2793
   PubMed Web of Science ®Google Scholar
• Gahrton G, Tura S, Ljungmann, Belanger C, Brandt L, Cavo M, et al. Allogeneic bone marrow transplantation in multiple myeloma. New England Journal of Medicine 1991; 325: 1267–1273
   PubMed Web of Science ®Google Scholar
• Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bjorkstrand B, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–1993 and 1994–1998 at European Group for Blood and Marrow Transplantation center. British Journal of Hematology 2001; 113: 209–216
   PubMed Web of Science ®Google Scholar
• Kröger N, Sayer H G, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation related mortality. Blood 2002; 100: 3919–3924
   PubMed Web of Science ®Google Scholar
• Maloney D, Molina A J, Sahebi F, Stockerl-Goldstein K E, Sandmaier B M, Bensinger W, et al. Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447–3454
   PubMed Web of Science ®Google Scholar
• Perez-Simon J A, Martino R, Alegre A, Tomas J F, De Leon A, Caballero D, et al. Chronic but not acute Graft versus host disease improves outcome in multiple myeloma patients after nonmyeloablative allogeneic transplantation. British Journal of Haematology 2003; 121: 104–108
   PubMed Web of Science ®Google Scholar
• Einsele H, Schäfer H, Hebart H, Bader P, Meisner C, Plasswilm L, et al. Follow up of patients with progressive multiple myeloma undergoing allografts after reduced intensity conditioning. British Journal of Haematology 2003; 121: 411–418
   PubMed Web of Science ®Google Scholar
• Lynch R G, Graff R J, Sirisinha S, Simms E S, Eisen H N. Myeloma proteins as tumor-specific transplantation antigens. Proceedings of the National Academy of Sciences (USA) 1972; 69: 1540–1544
   PubMed Web of Science ®Google Scholar
• Bendandi M. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. Expert Reviews in Anticancer Therapy 2001; 1: 65–72
   PubMedGoogle Scholar
• Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999; 94: 673–683
   PubMed Web of Science ®Google Scholar
• Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998; 91: 2459–2466
   PubMed Web of Science ®Google Scholar
• Reichardt V L, Okada C Y, Liso A, Benike C J, Stockerl-Goldstein K E, Engleman E G, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma–a feasibility study. Blood 1999; 93: 2411–2419
   PubMed Web of Science ®Google Scholar
• Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. British Journal of Haematology 2000; 108: 805–816
   PubMed Web of Science ®Google Scholar
• Kwak L W, Campbell M J, Czerwinski D K, Hart S, Miller R A, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. New England Journal of Medicine 1992; 327: 1209–1215
   PubMed Web of Science ®Google Scholar
• Hsu F J, Caspar C B, Czerwinski D, Kwak L W, Liles T M, Syrengelas A, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long-term results of a clinical trial. Blood 1997; 89: 3129–3135
   PubMed Web of Science ®Google Scholar
• Bendandi M, Gocke C D, Kobrin C B, Benko F A, Sternas L A, Pennington R, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Natural Medicine 1999; 5: 1171–1177
   PubMed Web of Science ®Google Scholar
• Liso A, Stockerl-Goldstein K E, Auffermann-Gretzinger S, Benike C J, Reichardt V, van Beckhoven A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biology of Blood Marrow Transplant 2000; 6: 621–627
   PubMed Web of Science ®Google Scholar
• Yi Q, Desikan R, Barlogie B, Munshi N. Optimizing dendritic cell-based immunotherapy in multiple myeloma. British Journal of Haematology 2002; 117: 297–305
   PubMed Web of Science ®Google Scholar
• Reichardt V L, Milazzo C, Brugger W, Einsele H, Kanz L, Brossart P. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica 2003; 88: 1139–1149
   PubMed Web of Science ®Google Scholar
• Brown R D, Pope B, Murray A, Esdale W, Sze D M, Gibson J, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001; 98: 2992–2998
   PubMed Web of Science ®Google Scholar
• Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002; 100: 230–237
   PubMed Web of Science ®Google Scholar
• Maas F, Woestenenck R, Zoetbrood A, Levenga H, Raymakers R, de Witte T, et al. The role of dendritic cell genotype in the induction of T-cell responses against hematopoietic malignant cells after allogeneic stem cell transplantation. Haematologica/The Hematology Journal 2005; 90(s1)59
   Google Scholar
• Rodríguez-Caballero A, García-Montero A C, Bueno C, Almeida J, Varro R, Chen R, et al. A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation. Laboratory Investigations 2004; 84: 1387–1398
   PubMed Web of Science ®Google Scholar
• Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for definition response relapse and progression in multiple myeloma after high-dose therapy. British Journal of Haematology 1998; 102: 1115–1123
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, Klingemann H G, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplantation 1995; 15: 825–828
   PubMed Web of Science ®Google Scholar
• Sullivan K M, Shulman H M, Storb R, Weiden P L, Witherspoon R P, McDonald G B, et al. Chronic graft-versus- host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267–276
   PubMed Web of Science ®Google Scholar
• Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 2004; 18: 139–145
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Hansson L, Osterborg A, Johnsen H E, Mellstedt H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 2003; 101: 4607–4610
   PubMed Web of Science ®Google Scholar
• Li Y, Bendandi M, Deng Y, Dunbar C, Munshi N, Jagannath S, et al. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood 2000; 96: 2828–2832
   PubMed Web of Science ®Google Scholar
• Nelson E L, Li X, Hsu F J, Kwak L W, Levy R, Clayberger C, et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 1996; 88: 580–589
   PubMed Web of Science ®Google Scholar
• Barrios Y, Cabrera R, Yanez R, Briz M, Plaza A, Fores R, et al. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica 2002; 87: 400–407
   PubMed Web of Science ®Google Scholar
• Weng W K, Czerwinski D, Timmerman J, Hsu F J, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. Journal of Clinical Oncology 2004; 22: 4665–4672
   PubMed Web of Science ®Google Scholar
• Kroger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A, et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004; 103: 4056–4061
   PubMed Web of Science ®Google Scholar
• Kroger N, Perez-Simon J A, Myint H, Klingemann H, Shimoni A, Nagler A, et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biology of Blood Marrow Transplant 2004; 10: 698–708
   PubMed Web of Science ®Google Scholar
• Banchereau J, Palucka A K. Dendritic cells as therapeutic vaccines against cancer. Natural Reviews in Immunology 2005; 5: 296–306
   PubMed Web of Science ®Google Scholar